Long-term clinical outcomes of Zika-associated Guillain-Barré syndrome

Figures & data

Disability characteristics of serologically diagnosed Zika Guillain–Barré syndrome (Z-GBS) cases with Brighton Criteria level 1 or 2 at 1 (n = 15) and 2 (n = 13) years follow-up post-GBS

Characteristics	1 Year follow-up	2 Year follow-up
Hughes Disability Score^Citation2, n/d (%)
Healthy	9/15 (60%)	5/13 (38%)
Minor symptoms but capable of running	3/15 (20%)	2/13 (15%)
Able to walk 5 m across an open space with support	2/15 (13%)	4/13 (31%)
Confined to bed or chair bound	1/15 (7%)	1/13 (8%)
HAQ-II Score^Citation12, median (IQR)	0 (0–0.08)	0.09 (0–0.55)
Use of wheelchair, n/d (%)	1/15 (7%)	1/13 (7%)
Pain score in last week, median (IQR) from 0 none to 100 maximum pain	5 (0–30)	40 (0–60)
General wellbeing score, median (IQR) from 0 “I feel well” to 100 “I feel very bad”	4 (0–20)	21 (0–50)
Mental health, n/d (%) in the last month
Frequently enjoying things	14/15 (93%)	12/13 (92%)
Frequently feel calm	11/15 (73%)	11/13 (85%)
Frequently feel nervous	2/15 (13%)	9/13 (69%)
Frequently feel depressed	3/15 (20%)	8/13 (62%)
Frequently feel nothing is going well	3/15 (20%)	5/13 (38%)

^aClinical Health Assessment Questionnaire 2 (CLIN-HAQ2) is a composite score between 0 (minimal loss of function) and 3 (completely disabled)¹³

HughesRAImmunotherapy for Guillain-Barré syndrome: a systematic reviewBrain20071302245225710.1093/brain/awm004

 PubMed Web of Science ®Google Scholar

FrenzenPDEconomic cost of Guillain-Barre syndrome in the United StatesNeurology200871212710.1212/01.wnl.0000316393.54258.d1

 PubMed Web of Science ®Google Scholar

WolfeFMichaudKPincusTDevelopment and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaireArthritis Rheumatol.2004503296330510.1002/art.20549

 PubMed Web of Science ®Google Scholar